FDA Qualifies AIM-NASH For MASH Trial Assessment
On December 9, 2025, the U.S. Food and Drug Administration qualified AIM-NASH, the first AI tool to assess metabolic dysfunction-associated steatohepatitis (MASH) in drug trials. The cloud-based system analyzes liver biopsy images to score fat, inflammation, and scarring and will be publicly available for the qualified context of use. The FDA said studies showed AIM-NASH results comparable to individual experts, potentially streamlining MASH clinical trials.
Key Points
- 1Qualifies AIM-NASH, a cloud AI analyzing liver biopsy images to score MASH pathology
- 2Standardizes assessments by matching individual expert evaluations in FDA validation studies
- 3Enables drug developers to adopt AIM-NASH across trials, reducing time and resource burdens
Scoring Rationale
Official FDA qualification and public availability make this highly actionable for drug developers; scope limited to MASH clinical context.
Sources
Public references used for this report.
Practice with real Health & Insurance data
90 SQL & Python problems · 15 industry datasets
250 free problems · No credit card
See all Health & Insurance problems
